BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

BioCryst announced new clinical data and real-world evidence for ORLADEYO (berotralstat), its oral prophylactic therapy for hereditary angioedema (HAE), showing consistent reductions in HAE attack burden and healthcare utilization. The company also presented post hoc analysis from the Phase 1b/2 ALPHA-STAR study of investigational navenibart, a long-acting monoclonal antibody plasma kallikrein inhibitor, demonstrating consistent attack rate reductions across patient subgroups and supporting ongoing Phase 3 evaluation.

06/12/2026, 7:00 AM • GlobeNewswire

BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update

BioCryst Pharmaceuticals reported Q1 2026 ORLADEYO net revenue of $148.3 million, up 11% year-over-year. The company announced a licensing agreement with Neopharmed Gentili for European commercial rights to navenibart, receiving $70 million upfront and up to $275 million in milestone payments. Patient enrollment in the navenibart pivotal study remains on track for completion by end of June 2026, with US regulatory filing expected by end of 2027. The company maintained its full-year 2026 revenue guidance of $625-645 million for ORLADEYO.

05/06/2026, 7:00 AM • GlobeNewswire

BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema

BioCryst Pharmaceuticals granted an Irish affiliate of Neopharmed Gentili exclusive European rights to commercialize navenibart for hereditary angioedema. BioCryst will receive $70M upfront, up to $275M in future milestone payments, and 18-30% royalties on sales. The agreement builds on their prior ORLADEYO business sale and supports BioCryst's strategy to focus on U.S. commercialization while strengthening its financial position.

05/04/2026, 7:00 AM • GlobeNewswire

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BioCryst Pharmaceuticals announced the appointment of Dr. Sandeep M. Menon as Chief Research and Development Officer. Dr. Menon brings extensive experience from leadership roles at Alnylam Pharmaceuticals and Pfizer, where he oversaw clinical development of multiple therapies including AMVUTTRA and PAXLOVID. The appointment comes as BioCryst advances its navenibart program toward potential FDA approval and builds on the commercial success of ORLADEYO and the recent acquisition of Astria Therapeutics.

04/06/2026, 7:00 AM • GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals announced that its compensation committee granted restricted stock units (RSUs) covering 65,850 shares of common stock to six newly-hired employees as inducement grants. The RSUs vest in four equal annual installments beginning one year from the grant date of March 2, 2026, subject to continued employment.

03/04/2026, 7:00 AM • Benzinga

BioCryst Reports Full Year 2025 Financial Results and Provides Business Update

BioCryst Pharmaceuticals achieved full-year profitability for the first time in company history in 2025, with ORLADEYO net revenue reaching $601.8 million (+38% y-o-y). The company received FDA approval for ORLADEYO oral pellets for children ages 2-11 and completed the acquisition of Astria Therapeutics to expand its HAE portfolio with navenibart. BioCryst maintained 2026 ORLADEYO revenue guidance of $625-645 million and reported record operating profit despite selling its European ORLADEYO business.

02/26/2026, 7:00 AM • GlobeNewswire

BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting

BioCryst Pharmaceuticals announced it will present nine abstracts on its hereditary angioedema (HAE) portfolio at the 2026 AAAAI Annual Meeting in Philadelphia. The presentations include six abstracts on ORLADEYO (berotralstat), an oral prophylactic therapy for HAE patients aged 2 and older, and three on navenibart, an investigational monoclonal antibody plasma kallikrein inhibitor. A late-breaking presentation will highlight positive interim results from the ALPHA-SOLAR trial showing sustained HAE attack suppression with navenibart administered every 3 or 6 months.

02/11/2026, 7:00 AM • GlobeNewswire

BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema

BioCryst Pharmaceuticals completed its $700 million acquisition of Astria Therapeutics, adding navenibart, a late-stage plasma kallikrein inhibitor in Phase 3 development for hereditary angioedema (HAE). The acquisition strengthens BioCryst's HAE portfolio alongside its leading oral therapy ORLADEYO, with navenibart potentially offering every-three and every-six month dosing options. BioCryst financed the deal with cash on hand and $396.6 million from a Blackstone financing facility, plus 37.3 million shares issued to Astria shareholders.

01/23/2026, 9:00 AM • GlobeNewswire

Halper Sadeh LLC Encourages ATXS, PCH, RYN Shareholders to Contact the Firm to Discuss Their Rights

Law firm investigating potential securities law violations and fiduciary duty breaches for multiple companies involving merger and acquisition transactions.

11/22/2025, 5:41 AM • GlobeNewswire

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

BioCryst will present four abstracts at the ACAAI Annual Scientific Meeting, focusing on pediatric hereditary angioedema (HAE) research, including long-term prophylaxis data for ORLADEYO in children aged 2 to <12 years and psychosocial impact studies.

10/23/2025, 7:00 AM • GlobeNewswire

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

BioCryst Pharmaceuticals announced it will acquire Astria Therapeutics for $700 million, adding a new product candidate (Navenibart) for hereditary angioedema treatment, with the deal expected to close in Q1 2026.

10/14/2025, 12:20 PM • Benzinga

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals granted stock options and restricted stock units to eight newly-hired employees, covering 115,000 shares and 91,450 shares respectively, as part of their employment inducement strategy.

10/03/2025, 7:00 AM • GlobeNewswire

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

BioCryst Pharmaceuticals sold its European ORLADEYO business to Neopharmed Gentili for $250 million upfront, with potential additional $14 million in milestones, focusing on simplifying operations and improving operating margin.

10/01/2025, 7:00 AM • GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst Pharmaceuticals granted nine newly-hired employees stock options to purchase 36,700 shares and restricted stock units covering 71,400 shares of company stock, with options priced at $8.29 per share and vesting in four equal annual installments.

09/03/2025, 7:00 AM • GlobeNewswire

Ionis Pharma Wins FDA Nod For First RNA-Targeted Therapy For Rare Genetic Swelling Disorder

The FDA approved Ionis Pharmaceuticals' Dawnzera, the first RNA-targeted medicine for preventing hereditary angioedema (HAE) attacks in patients 12 and older, demonstrating significant attack rate reduction in clinical trials.

08/21/2025, 2:24 PM • Benzinga